Diffuse large B-cell lymphoma is the most common subtype of malignant lymphoma and accounts for 33% of all cases of malignant lymphoma in Japan.[@b1] Diffuse large B-cell lymphoma usually arises *de novo* in lymph nodes, but can also be derived from extranodal organs. The WHO classification describes various special types of DLBCL, and DLBCLs harboring EBV in patients older than 50 years are termed EBV-positive DLBCL of the elderly (EBV-DLBCL of the elderly) as a new category.[@b2],[@b3] The EBV-DLBCL of the elderly category accounts for 8--10% of all DLBCL in Asian countries,[@b4] but \<5% in Western countries.[@b5],[@b6]

Epstein--Barr virus is the most common gamma herpes virus, and it has infected more than 90% of all adults. Most people are infected subclinically in childhood and maintain a latent infection throughout their life. During the process of infection, EBV attaches to B cells through the binding of viral gp350 protein to CD21 on the surface of B cells. Then, gp42 on EBV interacts with MHC class II molecules and triggers fusion with the host membrane.[@b7] The EBV is reactivated by various stimuli. Epstein--Barr virus-infected B cells are usually controlled by EBV-specific T cells, but they become uncontrolled when the host is immunodeficient. B cells infected with EBV sometimes become lymphoblastoid cell lines and obtain an unlimited ability to proliferate. Lymphoblastoid cell lines cause some lymphoid malignancies, including Burkitt lymphoma, extranodal natural killer/T-cell lymphoma, aggressive natural killer leukemia/lymphoma, angioimmunoblastic T-cell lymphoma, Hodgkin\'s lymphoma, immunodeficiency-associated lymphoproliferative disorders, and some DLBCLs.[@b8]

The standard treatment for DLBCL before the rituximab era was chemotherapy combined with CHOP. Since the introduction of rituximab into the clinic, R-CHOP has become the standard treatment for CD20-positive DLBCL.[@b9],[@b10] The outcome of DLBCL patients is improved with R-CHOP, but the impact on the prognosis of EBV-positive DLBCL patients remains controversial.[@b11]--[@b15]

We investigated the clinical features of patients with EBV-positive DLBCL and showed that the outcome of elderly patients with EBV-positive DLBCL treated with R-CHOP was still worse than other groups in this study.

Materials and Methods
=====================

Patients
--------

We reviewed the medical records of 289 patients who received a diagnosis of DLBCL at Tokai University Hospital (Isehara, Japan) and who were treated there and at affiliated hospitals between January 2007 and December 2011. Among 289 patients, 29 patients were excluded because no paraffin-embedded samples were available. Therefore, 260 cases were examined for the presence of EBV using formalin-fixed paraffin-embedded tissue sections.

A suitably constituted Ethics Committee of our institution approved the protocol for this research project, and the work was carried out according to this protocol. Our study conformed to the provisions of the Declaration of Helsinki in 1995.

Epstein--Barr virus-encoded RNA *in situ* hybridization and IHC
---------------------------------------------------------------

Epstein--Barr virus-encoded RNA *in situ* hybridization was carried out using a fluorescein-conjugated EBER oligonucleotide probe and the purified IgG fraction of a mouse monoclonal anti-fluorescein antibody (Leica, Newcastle, UK). For IHC, mouse mAbs against CD3, CD5, CD10, CD15, CD20, CD79a, BCL-2, BCL-6, and MUM-1 (Novocastra, Newcastle upon Tyne, UK), and CD30 (Clone CON6D; Spanish National Cancer Research Centre (CNIO), Madrid, Spain) were used as primary antibodies. Detection of signals for EBER-ISH and IHC was carried out using the Leica BOND-MAX fully automatic IHC system with the BOND Polymer Refine detection kit according to the manufacturer\'s instructions using BOND Epitope Retrieval Solution for 20 min for antigen retrieval (DS9800 and AR9640; Leica Microsystems, Tokyo, Japan). For EBER-ISH-positive cases, LMP-1 (Novocastra) and EBNA-2 antibody (Novocastra) were examined with IHC.

When more than 30% of large-sized cells were positive, the case was deemed "EBV-positive". The DLBCL subtypes of GCB or non-GCB were categorized using CD10, BCL-6, and MUM-1 according to Hans\' algorithm.[@b16] Cases that were unavailable for BCL-6 were categorized using CD10 and MUM-1 according to Chang\'s algorithm.[@b17] Epstein--Barr virus latency was classified as: latency I, LMP-1(−) EBNA-2(−); latency II, LMP-1(+) EBNA-2(−); and latency III, LMP-1(+) EBNA-2(+).

Clinical characteristics and statistical methods
------------------------------------------------

Comparisons of characteristics between EBV-positive and EBV-negative cases were examined with Fisher\'s exact test or the non-parametric Mann--Whitney *U*-test, as appropriate. Tumor responses were assessed with computed tomography and PET. Patients were classified by the best tumor response according to the response criteria for malignant lymphoma.[@b18] Overall survival was defined as the duration from the date of diagnosis of DLBCL to the date of death of any cause. Progression-free survival was defined as the duration from the date of diagnosis to the date of progressive or relapsed disease. The OS and PFS probabilities were estimated using the Kaplan--Meier method, and patients who were alive at the last follow-up were censored. The log--rank test was used to compare pairs of subgroups regarding survival. Multivariate analyses were carried out using Cox\'s proportional hazards regression analysis. Statistical analyses were carried out using the GraphPad Prism 6.0 (GraphPad Software, San Diego, CA) and EZR version 3.0.2.[@b19]

Results
=======

Patient selection, EBER-ISH, and IHC
------------------------------------

The EBER-ISH analysis showed 18 cases of DLBCL that harbored EBV among the 260 cases examined (6.9%). Among these 260 cases, 21 cases were excluded from analysis in this study for the following reasons: 1 case with HIV infection (EBV-positive); 4 cases with a history of methotrexate (EBV-positive, 2 cases; EBV-negative, 2 cases); 4 cases with primary large B-cell lymphoma of the central nervous system (EBV-negative); and 12 cases in which the clinical records were unavailable (EBV-positive, 1 case; EBV-negative, 11 cases). Finally, we analyzed 239 patients that included 14 cases of EBV-positive DLBCL and 225 cases of EBV-negative DLBCL, resulting in an EBV-positive rate of 6.0% (Table[1](#tbl1){ref-type="table"}). Because all EBV-positive DLBCL patients were older than 50 years, they satisfied the criteria of EBV-DLBCL of the elderly.

###### 

Details of patients with diffuse large B-cell lymphoma (DLBCL) who were excluded from this analysis

                                                      EBV-positive DLBCL   EBV-negative DLBCL
  --------------------------------------------------- -------------------- --------------------
  Total patients                                      18                   242
  Primary CNS DLBCL[†](#tf1-1){ref-type="table-fn"}   0                    4
  Immunodeficiency                                    3                    2
   Methotrexate                                       2                    2
   HIV infection                                      1                    0
  Unknown                                             1                    11
  No. of patients analyzed in this study              14                   225

Patients with primary central nervous system (CNS) DLBCL were excluded from analysis because rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone was not a treatment option. EBV, Epstein--Barr virus.

Clinical data are summarized in Table[2](#tbl2){ref-type="table"}. The median age was 71.5 years in EBV-positive patients and 68.0 years in EBV-negative patients (*P* = 0.3379). The percentages of patients aged over 60 years were 78.6% for EBV-positive and 75.6% for EBV-negative patients (*P *= 1.0000). The performance status was inferior in EBV-positive patients; the incidence of a performance status \>2 in EBV-positive patients was higher than that in EBV-negative patients (43.9% *vs* 17.8%, respectively; *P* = 0.0223). Extranodal disease affecting more than two organs was found in 12/14 EBV-positive cases (85.7%) and 121/204 EBV-negative cases (59.3%) *(P* = 0.0856). Eleven out of 12 EBV-positive cases were non-GCB types (91.7%). In EBV-negative cases, GCB and non-GCB types were found in 54 patients (25.0%) and 162 patients (75.0%), respectively. In EBV-positive DLBCL, seven patients showed latency II and four showed latency III.

###### 

Summary of clinical data of patients with Epstein--Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) (*n* = 14) and EBV-negative DLBCL (*n* = 225)

  Variable                               EBV-positive DLBCL (*n* = 14)   EBV-negative DLBCL (*n* = 225)   *P*-value
  -------------------------------------- ------------------------------- -------------------------------- ----------------------------------------
  Age, years, median (range)             71.5 (55--84)                   68.0 (22--92)                    0.3379[‡](#tf2-2){ref-type="table-fn"}
  Gender (male/female)                   8/6                             122/103                          1.0000[†](#tf2-1){ref-type="table-fn"}
                                         No. of cases (%)                No. of cases (%)                 *P*-value
  Over 60 years of age                   11 (78.6)                       170 (75.6)                       1.0000[†](#tf2-1){ref-type="table-fn"}
  ECOG PS 2--4                           6 (43.9)                        38/214 (17.8)                    0.0223[†](#tf2-1){ref-type="table-fn"}
  Ann Arbor stage III/IV                 9 (64.3)                        114/216 (52.8)                   0.5819[†](#tf2-1){ref-type="table-fn"}
  B symptoms, presence                   6 (43.9)                        57/208 (27.4)                    0.1067[†](#tf2-1){ref-type="table-fn"}
  Extranodal involvement (\>1 site)      12 (85.7)                       121/204 (59.3)                   0.0856[†](#tf2-1){ref-type="table-fn"}
  IPI, High intermediate/High            9 (64.3)                        96/202 (47.5)                    0.2749[†](#tf2-1){ref-type="table-fn"}
  LDH, IU/L, median (range)              339.5 (154--1798)               262.0 (132--5310)                0.1803[‡](#tf2-2){ref-type="table-fn"}
  LDH ≥ facility upper limit of normal   11 (78.6)                       135 (60.0)                       0.2580[†](#tf2-1){ref-type="table-fn"}
  IL2R, U/mL, median (range)             2740 (374--6780)                1300 (164--68 800)               0.1146[‡](#tf2-2){ref-type="table-fn"}
  IL2R ≥1000 U/mL                        10 (71.4)                       128/219 (58.4)                   0.2501[†](#tf2-1){ref-type="table-fn"}
  IgG, mg/dL, median (range)             1501 (561--2510)                1275 (300--3644)                 0.3785[‡](#tf2-2){ref-type="table-fn"}
  IgA, mg/dL, median (range)             226 (128--1473)                 251 (33--952)                    0.8541[‡](#tf2-2){ref-type="table-fn"}
  IgM, mg/dL, median (range)             78 (20--176)                    72 (8--1203)                     0.9227[‡](#tf2-2){ref-type="table-fn"}
  Pathological subtype                                                                                    
   GCB type                              1 (8.3)                         54 (25.0)                        0.3021[†](#tf2-1){ref-type="table-fn"}
   Activated B-cell (non-GCB) type       11 (91.7)                       162 (75.0)                       
   NA[†](#tf2-1){ref-type="table-fn"}    2                               9                                

Fisher\'s exact test.

Mann--Whitney *U*-test. ECOG, Eastern Cooperative Oncology Group; GCB, germinal center B cell; IL2R, interleukin 2 receptor; IPI, international prognostic index; LDH, lactate dehydrogenase; NA, not available; PS, performance status.

Treatment response
------------------

The various treatments are shown in Table[3](#tbl3){ref-type="table"}. Both R-CHOP and R-CHOP-like regimens were used for chemotherapy.

###### 

Summary of therapy and treatment responses in patients with Epstein--Barr virus (EBV)-positive and EBV-negative diffuse large B-cell lymphoma (DLBCL)

                                               EBV-positive DLBCL   EBV-negative DLBCL   *P*-value
  -------------------------------------------- -------------------- -------------------- ----------------------------------------
  Immunocompetent                              14                   225                  
    *No treatment*                             3                    11                   
    *Treatment*                                11                   214                  
  Chemotherapy, no rituximab                   3                    8                    
   Radiation                                   0                    3                    
  Rituximab only                               0                    5                    
  R plus chemotherapy                          8                    198                  
   R-CHOP                                      8                    160                  
   R-CHOP-like                                 0                    38                   
   R-COP                                       0                    16                   
   R-THP-COP                                   0                    14                   
   R-CHO                                       0                    4                    
   R-CHP                                       0                    2                    
  R-CO                                         0                    2                    
  No. of chemotherapy cycles, median (range)   4.5 (1--8)           6 (1--8)             0.0201[†](#tf3-1){ref-type="table-fn"}
  Response                                                                               
   CR                                          2 (25.0%)            147 (74.2%)          0.0060[‡](#tf3-2){ref-type="table-fn"}
   PR                                          2 (25.0%)            19 (9.6%)            
   SD or PD                                    4 (50.0%)            29 (14.6%)           
   NA                                           0                   3                    

Mann--Whitney *U*-test.

χ2-test. C, cyclophospahmide; CR, complete remission; H, doxorubicin; NA, not available; O, vincristine; P, prednisolone; PD, progressive disease; PR, partial response; R, rituximab; SD, stable disease; THP, pirarubicin.

The R-CHOP and R-CHOP-like regimens were given to 8/14 EBV-positive and 198/225 EBV-negative patients. The median number of R-CHOP cycles was 4 (range, 1--8) in EBV-positive patients and 6 (range, 1--8) in EBV-negative patients. Treatment was discontinued for various reasons in 5/8 EBV-positive patients and 30/198 EBV-negative patients *(P* = 0.0201). Among EBV-positive patients, two patients died of infection in the nadir phase during chemotherapy, one patient discontinued treatment due to PD, and one patient refused to continue chemotherapy due to an adverse drug reaction. Two EBV-positive patients showed CR (25%), two showed partial response (25%), and four showed stable disease/PD (50%). In contrast, 147 EBV-negative patients showed CR (74.2%), 19 patients showed partial response (9.6%), and 29 patients showed stable disease/PD (14.6%). The overall response rate was better in EBV-negative than EBV-positive patients (*P* = 0.0060).

Survival
--------

The median follow-up time of surviving patients was 25.2 months (range, 0.8--71.3 months). Median OS was 8.7 months in EBV-positive patients and was not reached in EBV-negative patients *(P* \< 0.0001; Fig.[1](#fig01){ref-type="fig"}). Three EBV-positive patients could not receive chemotherapy because their general condition was poor and disease progression was rapid.

![Overall survival (OS) in immunocompetent Epstein--Barr virus (EBV)-positive versus EBV-negative patients with diffuse large B-cell lymphoma. The median OS in EBV-positive patients was 8.7 months; OS could not be determined in EBV-negative patients. Hazard ratio = 3.9; 95% confidence interval, 4.0--49.3; *P* \< 0.0001.](cas0105-1170-f1){#fig01}

Median OS and PFS were 8.7 and 6.8 months, respectively, in EBV-positive patients treated with R-CHOP/R-CHOP-like regimens. Both OS and PFS were worse in EBV-positive patients than in EBV-negative patients (*P* = 0.0002, *P* \< 0.0001, respectively; Fig.[2](#fig02){ref-type="fig"}). Among eight patients who received R-CHOP/R-CHOP-like regimens, four died without achieving CR. All three patients with latency III died \<1 year after diagnosis. Two of them were resistant to chemotherapy. No difference in OS or PFS was found between latency III and latency II (Table[4](#tbl4){ref-type="table"}). We also did not find a difference in OS or PFS between the polymorphous type versus the large-cell type in EBV-positive DLBCL (Table[4](#tbl4){ref-type="table"}). Among EBV-negative patients, 49 died and 149 were alive. Among the 149 alive patients, 115 maintained relapse-free survival after achieving the first CR.

###### 

Details of clinical data for patients with Epstein--Barr virus-positive diffuse large B-cell lymphoma (*n* = 14)

  No.   Age, years/gender   PS   CS       IPI   Extranodal disease              CD20   CD15   CD30   EBER-ISH   LMP1   EBNA2   Latency   GCB/non-GCB   Morphological subtype   Others                   LDH (IU/L)   IL2R (U/mL)   IgG (mg/dL)   IgA (mg/dL)   IgM (mg/dL)   Therapy         No. of cycles   Response   OS (months)   PFS (months)   Outcome
  ----- ------------------- ---- -------- ----- ------------------------------- ------ ------ ------ ---------- ------ ------- --------- ------------- ----------------------- ------------------------ ------------ ------------- ------------- ------------- ------------- --------------- --------------- ---------- ------------- -------------- ---------------------------------------------------------------
  1     59/F                3    IVA      HI    Lung                            ++     −      \+     ++         ++     −       II        Non-GCB       Poly                    Necrosis                 154          1250          1069          190           176           R-CHOP          5               CR         44.6          8.6            Relapsed, treated with Bendamustine, alive, 2nd CR
  2     80/F                1    IIIB     HI    Skin, pleurae                   +++    −      \+     +++        \+     −       II        Non-GCB       Large                   Plasma differentiation   293          1990          1501          226           88            R-CHOP          4               PR         26.6          6.9            Progressive, treated with CEPP/VP16/rituximab, alive, 2nd CR
  3     64/M                0    IIA      LI    Stomach                         +++    −      −      ++         ++     −       II        Non-GCB       Poly                    None                     209          688           2510          396           78            R-CHO           6               CR         43.7          43.7           Alive, CR
  4     78/F                0    IIA      LI    Intraoral ulcer                 +++    −      −      +++        ++     \+      III       Non-GCB       Large                    None                    249          374           1279          238           119           R-CH (THP) OP   6               PD         10.2          6.7            Refractory to R-CPA-VP16/VP16/R-MIT-MCNU-VP16-Dex, died
  5     77/F                1    IIIB     HI    Retroperitoneal tumor           +++    −      ++     +++        +++    \+      III       Non-GCB       Large                    None                    1677         3570          1421          149           52            R-CHOP          2               PD         6.0           2.4            Refractory to EPOCH/R-DeVIC, died
  6     69/M                2    IIIB     LI    Liver                           ++     −      −      \+         ++     −       II        Non-GCB       Poly                    HRS cell                 219          6780          1573          1473          67            R-CHOP          3               PD         3.0           3.0            Sepsis, progressive disease, died
  7     55/F                4    IIB      HI    Abdominal tumor (soft tissue)   +++    −      +++    +++        ++     −       II        Non-GCB       Large                   None                     496          4520          634           174           71            R-CHOP          8               PR         7.2           7.2            Pneumonia, progressive disease, died
  8     69/F                0    IA       LI    Intraoral ulcer                 +++    −      −      +++        +++    \+      III       Non-GCB       Large                   None                     363          1390          561           128           20            R-CHOP          1               PD         1.3           1.3            Pneumonia, alveolar hemorrhage, died
  9     63/M                NA   IV^\*^   H     None                            ++     −      ++     \+         ++     −       II        Non-GCB       Poly                    HRS cell                 1798         9710          2001          189           113           No treatment    0               NA.        0.0           0.0            DIC, cerebral hemorrhage, died
  10    76/M                4    IV^\*^   H     Femur tumor                     ++     −      −      +++        ++     \+      III       Non-GCB       Poly                    None                     316          NA            NA            NA            NA            No treatment    0               NA.        0.4           0.4            Chose the best supportive care, died
  11    79/M                0    IIA      LI    Left thoracic tumor, rib        −      NA     NA     \+         NA     NA      NA        Non-GCB       Poly                    None                     370          952           2424          305           91            COP             8               PD         13.6          10.7           Relapse, chose the best supportive care after radiation, died
  12    74/M                4    IVB      HI    Lung                            −      \+     \+     +++        \+     −       II        NA            Poly                    Plasma differentiation   394          3530          1505          495           30            No treatment    0               NA.        0.0           0.0            Pneumonia by tumor invasion, died
  13    59/M                4    IVA      H     Liver, small intestine          −      \+     −      +++        NA     NA      NA        GCB           Large                   None                     768          12700         605           162           42            COP             1               PD         0.9           0.9            Progressive disease, died
  14    84/M                1    IIIB     HI    None                            ++     −      +++    ++         NA     NA      NA        NA            Poly                    HRS cell                 220          2740          2418          454           129           COP             6               CR         18.6          15.0           Relapse, chose the best supportive care, died

CEPP, cyclophosphamide, etoposide, procarbazine, prednisolone; CHO, cyclophosphamide, doxorubicin, vincristine; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; CPA, cyclophosphamide; CR, complete remission; CS, clinical stage; DeVIC, carboplatin, etoposide, interferon, dexamethasone, granulocyte-colony stimulating factor; Dex, dexamethasone; EBER-ISH, Epstein--Barr virus-encoded RNA *in situ* hybridization; EBNA, Epstein--Barr virus nuclear antigen antibody; EPOCH, rituximab, etoposide, doxorubicin, vincristine, cyclophosphamide, prednisolone; F, female; GCB, germinal center B cell; H, high; HI, high intermediate; IL2R, interleukin 2 receptor; IPI, international prognostic index; Large, large-cell type; LDH, lactate dehydrogenase; LI, low intermediate; LMP, latent membrane protein; M, male; MCNU, ranimustine; MIT, mitoxantrone; NA, not available; OS, overall survival; PD, progressive disease; PFS, progression-free survival; Poly, polymorphous type; PR, partial response; PS, performance status; R, rituximab; THP, pirarubicin; VP16, etoposide.

![Survival analysis in patients with diffuse large B-cell lymphoma (DLBCL) treated with chemotherapy regimens similar to rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone. (a) Overall survival (OS). The median OS in Epstein--Barr virus (EBV)-positive DLBCL patients was 8.7 months; OS could not be determined in EBV-negative patients. Hazard ratio = 4.3; 95% confidence interval, 3.6--121.6; *P* = 0.0002. (b) Progression-free survival (PFS). The median PFS in EBV-positive DLBCL patients was 6.8 months; median PFS could not be determined in EBV-negative patients. Hazard ratio = 5.6; 95% confidence interval, 13.0--384.6; *P* \< 0.0001.](cas0105-1170-f2){#fig02}

Multivariate analyses
---------------------

We carried out a Cox\'s proportional hazard regression analysis that included the following variables: age; EBV present; PS; clinical stage; B symptoms present; extranodal disease; LDH levels; interleukin-2 receptor levels; and GCB or non-GCB subtypes. The EBV, PS, and LDH levels were independent risk factors (*P* = 0.0014, 0.0007, and 0.0070, respectively). Among them, EBV had the highest hazard ratio (HR: 4.6. 95% confidence interval: 1.8--11.8) (Table[5](#tbl5){ref-type="table"}).

###### 

Summary of risk factors for prognosis in patients with diffuse large B-cell lymphoma, using multivariable analysis (*n* = 14)

                                     Univariate analysis[†](#tf5-1){ref-type="table-fn"}   Multivariate analysis[‡](#tf5-2){ref-type="table-fn"}                     
  ---------------------------------- ----------------------------------------------------- ------------------------------------------------------- ----------------- --------
  Age                                                                                                                                                                
   ≥60 years                         2.0 (1.1--3.8)                                        0.02039                                                 1.6 (0.8--3.3)    0.1911
  EBV                                                                                                                                                                
   Positive                          4.2 (2.1--8.2)                                        \<0.00010                                               4.6 (1.8--11.8)   0.0014
  PS                                                                                                                                                                 
   2--4                              5.6 (3.4--9.1)                                        \<0.00010                                               3.3 (1.7--6.7)    0.0007
  Clinical stage                                                                                                                                                     
   III--IV                           3.2 (1.9--5.5)                                        \<0.00010                                               1.5 (0.7--3.1)    0.2616
  B symptoms                                                                                                                                                         
   Present                           2.5 (1.5--4.0)                                        0.00040                                                 1.0 (0.5--2.0)    0.9379
  Extranodal disease                                                                                                                                                 
   ≥1 site                           2.7 (1.6--4.7)                                        0.00030                                                 1.0 (0.5--2.3)    0.9359
  LDH levels                                                                                                                                                         
   ≥Facility upper limit of normal   4.2 (2.6--6.7)                                        \<0.00010                                               3.3 (1.4--7.7)    0.0070
  IL2R levels                                                                                                                                                        
   ≥1000 U/mL                        4.2 (2.3--7.7)                                        \<0.00010                                               1.2 (0.5--2.8)    0.6597
  Subtype                                                                                                                                                            
   Non-GCB                           2.2 (1.1--3.4)                                        0.02670                                                 1.9 (0.8--4.2)    0.1324

Log--rank test.

Cox\'s proportional hazards regression analysis. CI, confidence interval; GCB, germinal-center B cell; HR, hazard risk; IL2R, interleukin 2 receptor; LDH, lactate dehydrogenase; PS, performance status.

Discussion
==========

We carried out a clinicopathological analysis of DLBCL with special interest in EBV. The percentage of patients with EBV infection (6.9%) among all cases of DLBCL in our data was equivalent to previously reported data from Asian countries.[@b8],[@b11],[@b12] All patients with EBV-positive DLBCL met the criteria of EBV-DLBCL of the elderly, proposed by WHO.

In our analysis, patient characteristics between those who were EBV-positive and those who were EBV-negative were almost equivalent except for the performance status *(P* = 0.0223) and a trend towards extranodal disease (*P* = 0.0856). Epstein--Barr virus-positive DLBCL tends to develop extranodal involvement in 70% of patients;[@b11],[@b20],[@b21] DLBCL generally involves extranodal organs such as the gastrointestinal tract, skin, lungs, and tonsils.[@b22] Differences in extranodal organ involvement between EBV-positive and EBV-negative cases are unknown.

Several studies regarding the prognosis of EBV-positive DLBCL have been reported. Morales *et al*.[@b12] reported that EBV is an independent prognostic factor associated with *de novo* nodal DLBCL, before the rituximab era. This study analyzed six patients with EBV-positive DLBCL and 51 patients with EBV-negative DLBCL. The median OS rates in EBV-positive DLBCL and EBV-negative DLBCL patients were 6.5 and 47 months, respectively, and patients with EBV-positive DLBCL showed an inferior prognosis compared to those with EBV-negative DLBCL (*P* = 0.001). Park *et al*.[@b8] reported that DLBCL patients who are EBER-ISH-positive show a more rapidly deteriorating clinical course with poorer treatment response, survival, and PFS. They analyzed 34 patients with EBV-positive DLBCL and 346 patients with EBV-negative DLBCL. Epstein--Barr virus-encoded RNA positivity was significantly associated with age older than 60 years (*P* = 0.005), more advanced stage (*P *\< 0.001), involvement of more than one extranodal site (*P *= 0.009), higher international prognostic index (the international prognostic index includes age \>60 years, PS \>2, number of extranodal sites \>2, stage \>III, and LDH level \>normal) (*P* = 0.015), presence of B symptoms (*P* = 0.004), and poorer outcome following initial treatment (*P *= 0.006). The EBER-positive patients with DLBCL showed significantly poorer OS (EBER-positive *vs* EBER-negative, *P* = 0.026) and PFS (EBER-positive *vs* EBER-negative, *P* = 0.018). Both reports arrived at the same conclusion: that the presence of EBV leads to a more rapidly deteriorating clinical course with poorer treatment response and survival.

In contrast, Ahn *et al*. retrospectively analyzed 222 elderly patients (≥50 years) with DLBCL who received R-CHOP chemotherapy and evaluated the state of EBER. Eighteen cases (8.1%) were EBER-positive. At a median follow-up of 32.8 months, no significant difference was found in OS between the groups (*P* = 0.627). The EBV-positive DLBCL patients with early interruption of R-CHOP chemotherapy showed a trend toward a high EBV DNA titer (≥1000 copies/mL; *P* = 0.091). Thus, the EBV-positive tumoral status of elderly DLBCL patients who undergo R-CHOP chemotherapy may not predict their survival but their EBV status may contribute to the early interruption of R-CHOP chemotherapy.[@b15] In our study, we observed that OS and PFS of EBV-positive DLBCL patients were still lower than EBV-negative DLBCL, even after introduction of rituximab. Although the survival data are controversial between the two studies, they share some common features. For instance, both studies recognized that the overall response rate was worse in patients with EBV-positive DLBCL compared to those with EBV-negative DLBCL, and R-CHOP was interrupted early more frequently compared with EBV-negative DLBCL. Because the incidence of EBV-positive DLBCL of the elderly is low, a limitation is the small number of EBV-positive DLBCL patients in both studies. Based on these results, a multicenter study is needed to clarify the controversies regarding EBV-positive DLBCL.

Among 14 patients with EBV-positive DLBCL in our study, four patients showed latency III. Latency I is associated with EBV-related Burkitt lymphoma, latency II with classical Hodgkin\'s lymphoma and T-cell non-Hodgkin\'s lymphoma, and latency III occurs mainly in immunocompromised individuals suffering from post-transplant lymphoproliferative disorders and HIV-associated lymphoproliferative disorders and lymphoblastoid cell lines.[@b23] In general, a more intense immunosuppressive status is associated with a higher latency status. However, none of our patients was immunosuppressed. Patients with latency III died within 1 year of diagnosis, regardless of treatment with rituximab. Although no significant difference in survival was found, the outcome of latency III patients tended to be poor compared with that of latency II patients. Yoshino *et al*.[@b24] reported that EBV-positive DLBCL is resistant to standard chemotherapy. In this study, patients with latency III also showed resistance to chemotherapy.

In addition, we showed that the majority of patients classified as having EBV-positive DLBCL of the elderly were non-GCB types, which is a subtype with poor prognosis, and this may be another reason for the inferior prognosis. In EBV-positive DLBCL of the elderly, according to the WHO classification, age of more than 70 years and the presence of B symptoms are negative prognostic factors.[@b4],[@b11],[@b25] The proportion of the non-GCB type increases and reflects a change in the B-cell population during aging.[@b26] Thus, advanced age may lead to poor prognosis. Because age was not related to positive or negative EBV status in our study, we suggest that the latency status is a risk factor for developing the non-GCB type. Montes-Moreno *et al*.[@b27] reported that EBV infection may play a direct and additional role in activation of the nuclear factor-κB pathway. According to their report, EBV-positive DLBCL in the elderly is an aggressive and clonal B-cell neoplasm with prominent nuclear factor-κB pathway activation in the neoplastic cells. Epstein--Barr virus-encoded RNA positivity has an adverse impact on OS and PFS in patients with non-GCB DLBCL but not GCB DLBCL.[@b8] However, the detailed mechanism of conversion to more malignant clones in the presence of EBV is unknown. Infection with EBV in patients with non-GCB DLBCL may lead to further resistance to chemotherapy.

In summary, rituximab, which improved the outcome of DLBCL patients, did not show sufficient efficacy in EBV-positive DLBCL patients. Patients with latency III were more resistant to chemotherapy. Further investigation of EBV-positive DLBCL patients based on their latency status and IHC phenotype is needed.
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BCL

:   B-cell chronic lymphocytic leukemia/lymphoma

CHOP

:   cyclophosphamide, doxorubicin, vincristine, and prednisolone

CR

:   complete remission

DLBCL

:   diffuse large B-cell lymphoma

EBER

:   Epstein--Barr virus-encoded RNA

EBNA-2

:   Epstein--Barr virus nuclear antigen-2

EBV

:   Epstein--Barr virus

GCB

:   germinal center B cell

IHC

:   immunohistochemistry

ISH

:   *in situ* hybridization

LDH

:   lactate dehydrogenase

LMP-1

:   latent membrane protein-1

MUM-1

:   multiple myeloma oncogene-1

OS

:   overall survival

PD

:   progressive disease

PFS

:   progression-free survival

PS

:   performance status

R-CHOP

:   rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone

WHO

:   World Health Organization
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